Glaukos Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
13analysts covering
FY Revenue (est.)
$690.9Mnext fiscal year
FY EPS (est.)
-$0.29next fiscal year
Monitoring Framework
Key Performance Indicators
Net Sales Quarterly150.6MTarget: 620000000 to 635000000
Non-GAAP Gross Margin Quarterly84.0%Target: Maintain or improve
Watch Items
- iDose TR Commercial Launch and ReimbursementTrigger: Slower-than-expected physician adoption or local coverage determination (LCD) headwindsAction: Increase sales force training, expand patient support services, and engage with local MACs
- Epioxa Commercial Launch and J-Code ImplementationTrigger: Reimbursement friction following the July 1, 2026 J-code effective dateAction: Leverage Glaukos Patient Services to streamline prior authorizations and billing processes
Research as of 2 Sep 2026